Product Description
NOV1803 (DNP002) is a humanized anti-CEACAM6 antibody. It can bind and destroy both cancer cells and MDSC. NOV1803’s epitope is B domain of CEACAM6, therefore it does not block the CEACAM1 and CEACAM6 interaction. Rather, by binding the membrane-proximal region of CEACAM6, NOV1803 strongly induces ADCC. Ex vivo studies with advanced gastric cancer (AGC) patients showed the almost complete depletion of cancer cells following the activation of autologous immune cells. Besides, NOV1803 effectively depleted the MDSC (myeloid-derived suppressor cells) in Ex Vivo studies using the whole blood of AGC patients. Also, strong tumor growth inhibition was shown in several mouse models including NSCLC, gastric cancer, and colon cancer. (Sourced from: https://www.ncc.re.kr/main.ncc?uri=english/sub02_CancerTherapeutics)
Mechanisms of Action: CEACAM6 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Kumho HT Inc.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Korea
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCC2021-0034 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2024-12-01 |